Table 1_Baseline serum metabolites predict fractures in individuals who were Black and had

571 participants in the ACCORD clinical trial, with an average age of 62.1 years, had 465 targeted metabolites analyzed from baseline serum samples. The data, authored by Carolyn Chlebek and shared under CC-BY-4.0, compares the metabolome of Black patients with type 2 diabetes who later fractured versus those who did not. One metabolite, 7,8-dihydrofolate, was significantly higher in participants who later fractured.

Use Cases

• Identify predictive serum metabolite biomarkers for fracture risk based on the analysis of 465 targeted metabolites.
• Study the relationship between the tricarboxylic acid cycle and skeletal fragility in type 2 diabetes.
• Investigate population-specific metabolic mechanisms for fracture risk, focusing on an understudied Black patient cohort.
• Validate findings from the ACCORD BONE study in other clinical trial datasets.

Strengths

• Data originates from the ACCORD randomized clinical trial (NCT00000620), a well-defined study.
• Focuses on an understudied population (Black patients with type 2 diabetes) regarding fracture risk.
• Analyzes a targeted panel of 465 serum metabolites from 571 participants.

Limitations

• The dataset is very small at 40.1 KB, suggesting it may be summary results rather than raw data.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for machine learning.

Provenance

Source

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial; serum samples from the NHLBI Biologic Specimen and Data Repository.

Collection Method

Analysis of 465 targeted metabolites in baseline serum samples from trial participants.

Freshness

Last updated 2026-06-02 04:21:28; freshness should be verified.